Video

Living In a Targeted Therapy Revolution of NSCLC

Author(s):

Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Related Videos
Marina Chiara Garassino, MD
Nicolas Girard, MD
Yelena Y. Janjigian, MD
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicolas Girard, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Shirish M. Gadgeel, MD
Jacob Sands, MD
Related Content
John V. Heymach, MD, PhD
October 9th 2024

ODAC Weighs In on the Future of Perioperative Trial Designs in Resectable NSCLC

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Isabel Preeshagul, DO, MBS, of Memorial Sloan Kettering Cancer Center
October 7th 2024

Expanding Treatment Arsenal Renews Hope for Improved Outcomes in Limited and Extensive SCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
October 5th 2024

The OncFive: Top Oncology Articles for the Week of 9/29

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology